Reata Pharmaceuticals Stock Current Liabilities
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Reata Pharmaceuticals fundamentals help investors to digest information that contributes to Reata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reata Stock. The fundamental analysis module provides a way to measure Reata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reata Pharmaceuticals stock.
Reata |
Reata Pharmaceuticals Company Current Liabilities Analysis
Reata Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Reata Pharmaceuticals Current Liabilities | 59.63 M |
Most of Reata Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Reata Pharmaceuticals has a Current Liabilities of 59.63 M. This is 96.6% lower than that of the Pharmaceuticals sector and 89.02% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.25% higher than that of the company.
Reata Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reata Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics of similar companies.Reata Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Reata Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X | |||
| Price To Sales | 414.73 X | |||
| Revenue | 2.22 M | |||
| Gross Profit | (167.63 M) | |||
| EBITDA | (269.02 M) | |||
| Net Income | (311.9 M) | |||
| Cash And Equivalents | 481.47 M | |||
| Cash Per Share | 13.19 X | |||
| Total Debt | 119.46 M | |||
| Debt To Equity | 2.08 % | |||
| Current Ratio | 10.60 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | (204.27 M) | |||
| Short Ratio | 2.81 X | |||
| Earnings Per Share | (2.62) X | |||
| Target Price | 172.45 | |||
| Number Of Employees | 321 | |||
| Beta | 1.42 | |||
| Market Capitalization | 6.57 B | |||
| Total Asset | 514.49 M | |||
| Retained Earnings | (1.57 B) | |||
| Working Capital | 338.81 M | |||
| Current Asset | 87.28 M | |||
| Current Liabilities | 59.63 M | |||
| Z Score | 27.78 | |||
| Net Asset | 514.49 M |
About Reata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |